oppenheimer - Search News

Alumis draws Outperform at Oppenheimer

Alumis draws Outperform at Oppenheimer on valuation disconnect

Oppenheimer launched its coverage of Alumis (NASDAQ:ALMS) with an Outperform recommendation and a 12–18-month price target of $32 on Thursday, noting that despite the potential in its pipeline, the company continues to trade near its cash level.

Business Insider · 9h

Alumis initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Alumis (ALMS) with an Outperform rating and $32 price target The company is focused on delivering

Hosted on MSN · 8h

Oppenheimer sets Alumis stock with Outperform, $32 target

Oppenheimer initiated coverage on Alumis Inc (NASDAQ:ALMS) with an Outperform rating and a price target of $32.00. The firm's analysts highlighted the biopharmaceutical company's focus on developing oral solutions for inflammatory and autoimmune disorders.

Christopher Nolan, Oppenheimer

Deadline on MSN · 1d

Christopher Nolan Reunites With Benny Safdie On His Adaptation Of ‘The Odyssey' At Universal

After working together on Oppenheimer, Christopher Nolan looks to have found a new role for Benny Safdie in his next event film as sources tell Deadline Safdie has joined the ensemble of Universal’s The Odyssey,

The News International · 6h

‘Oppenheimer’ star to join Christopher Nolan’s ‘Odyssey’ adaptation

Christopher Nolan has recently announced his reunion with Oppenheimer star Benny Safdie for his next movie.Safdie, who appeared as physicist Edward Teller in Nolan’s Oscar-winning movie,

Total Film on MSN · 9h

Another Oppenheimer actor is reuniting with Christopher Nolan for his next movie The Odyssey as filming begins next month

Benny Safdie is the latest actor to join the cast of The Odyssey, the next movie from Christopher Nolan, according to The Hollywood Reporter. Other confirmed cast members include Safdie's Oppenheimer co-star Matt Damon,

9hon MSN

Trump's Mass Deportation Plans Attacked in Home State Newspaper: 'Insane'

Andres Oppenheimer, a columnist for the "Miami Herald," said the Trump administration is targeting illegal immigrants with ...

cryptopolitan on MSN1d

Oppenheimer downgrades Apple, cites weakening iPhone sales and AI innovation worries

Oppenheimer downgraded Apple from "outperform" to "perform" because it is struggling to adapt to a competitive AI landscape.

Jewish Telegraphic Agency2d

The Jewish story behind ‘Oppenheimer,’ explained

(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...

Card Collecting Reaches Absurd New Heights As J. Robert Oppenheimer (Yes, That One) Now Has A Rookie Card: Reactions

The card collecting industry has exploded in recent years to such an extent that industry leader Topps is now producing a Robert Oppenheimer card that's ...

3don MSN

Chip equipment stocks may see 'unexpected' upside from DeepSeek: Oppenheimer

Amid the financial shock waves being sent by the release of DeepSeek's open source artificial intelligence R1 model, ...

Seeking Alpha on MSN3d

Top momentum subsectors according to Oppenheimer: capital markets, software, and more

Within financials ( XLF ), Wald mentioned capital markets and the SPDR S&P Capital Markets ETF ( KCE) as a top idea, ...

3don MSN

‘Wonka,’ ‘Dune 2,’ ‘Oppenheimer’ Drive U.K. Home Entertainment to Record $6.4 Billion Year

British consumers’ appetite for home entertainment reached new heights in 2024, with the sector surpassing £5.1 billion ($6.4 ...

When Christopher Nolan’s Red Paper Script For Oppenheimer Left Robert Downey Jr. Feeling Hypnotized: “You Forget It As Soon As You Read”

Did you know Christopher Nolan’s Oppenheimer script on his iconic red paper left Robert Downey Jr. nearly hypnotized? Read on ...

Oppenheimer Remains a Buy on Cf Industries Holdings (CF)

In a report released yesterday, Kristen Owen from Oppenheimer maintained a Buy rating on Cf Industries Holdings (CF – Research Report), with a ...

1hon MSN

Why Alumis (ALMS) Stock Is Advancing Today

Drug maker Alumis (ALMS) is climbing 7% after investment bank Oppenheimer started coverage of the name with an Outperform ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Alumis draws Outperform at Oppenheimer

Christopher Nolan, Oppenheimer

Related topics